ReviewFrontiers in immunology2022
Nanomaterials: A powerful tool for tumor immunotherapy.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 20 citations in OpenAlex.
- Advanced integrated SERS-based strategies for the early diagnosis of upper gastrointestinal cancers.Journal of nanobiotechnology · 2026Review
- Biomaterial-based strategies for postoperative residual tumors: From margin clearance to immune control and tissue repair.Materials today. Bio · 2026Review
- Biomimetic Polymer-Based Nanomaterials for Immune-Responsive Hepatocellular Carcinoma Therapy.International journal of nanomedicine · 2026Review
- Overcoming barriers in primary bone cancer: Nanomaterial-enabled immunotherapy.Materials today. Bio · 2025Review
- Recent advances in biomimetic nanodelivery systems for cancer Immunotherapy.Materials today. Bio · 2025Review
- Periodic Table of Immunomodulatory Elements and Derived Two-Dimensional Biomaterials.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Self-Assembled Nanoparticles: Overcoming Limitations of Conventional Nanomedicines for Enhanced Tumor Therapy.International journal of nanomedicine · 2025Review
- Nanomaterial-Enhanced Immunotherapy: Advancing T-Cell-Based Treatments for Bladder Cancer.International journal of nanomedicine · 2025Review
- Modulation of the immune microenvironment using nanomaterials: a new strategy for tumor immunotherapy.Frontiers in immunology · 2025Review
- Nanomaterials for Theranostic Management of Oral Cancer: Advances in Imaging, Biosensing, Targeted Delivery, and Multimodal Synergistic Therapy.International journal of nanomedicine · 2025Review
- Peptides as Versatile Regulators in Cancer Immunotherapy: Recent Advances, Challenges, and Future Prospects.Pharmaceutics · 2025Review
- PI3K/AKT/mTOR and PD‑1/CTLA‑4/CD28 pathways as key targets of cancer immunotherapy (Review).Oncology letters · 2024Review
- Crystallinity of covalent organic frameworks controls immune responses.Nature communications · 2024Article
- Synergistic Photothermal Therapy and Chemotherapy Enabled by Tumor Microenvironment-Responsive Targeted SWCNT Delivery.International journal of molecular sciences · 2024Article
- The role of cGAS in epithelial dysregulation in inflammatory bowel disease and gastrointestinal malignancies.Frontiers in pharmacology · 2024Review
- Nanomaterials: leading immunogenic cell death-based cancer therapies.Frontiers in immunology · 2024Review
- Nanomaterials in tumor immunotherapy: new strategies and challenges.Molecular cancer · 2023Review
- Carbon Nanomaterials: Emerging Roles in Immuno-Oncology.International journal of molecular sciences · 2023Review
- Immune checkpoint blockade for locally advanced or recurrent/metastatic cervical cancer: An update on clinical data.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer represents the leading global driver of death and is recognized as a critical obstacle to increasing life expectancy. In recent years, with the development of precision medicine, significant progress has been made in cancer treatment. Among them, various therapies developed with the help of the immune system have succeeded in clinical treatment, recognizing and killing cancer cells by stimulating or enhancing the body's intrinsic immune system. However, low response rates and serious adverse effects, among others, have limited the use of immunotherapy. It also poses problems such as drug resistance and hyper-progression. Fortunately, thanks to the rapid development of nanotechnology, engineered multifunctional nanomaterials and biomaterials have brought breakthroughs in cancer immunotherapy. Unlike conventional cancer immunotherapy, nanomaterials can be rationally designed to trigger specific tumor-killing effects. Simultaneously, improved infiltration of immune cells into metastatic lesions enhances the efficiency of antigen submission and induces a sustained immune reaction. Such a strategy directly reverses the immunological condition of the primary tumor, arrests metastasis and inhibits tumor recurrence through postoperative immunotherapy. This paper discusses several types of nanoscale biomaterials for cancer immunotherapy, and they activate the immune system through material-specific advantages to provide novel therapeutic strategies. In summary, this article will review the latest advances in tumor immunotherapy based on self-assembled, mesoporous, cell membrane modified, metallic, and hydrogel nanomaterials to explore diverse tumor therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.